Revenue growth is due to growth in Teva's US generics business, the company's main market, among other things due to sales of ...

Sarepta Therapeutics (Nasdaq: SRPT) has announced it will cease development of SRP-5051, an experimental drug for Duchenne ...

The global auto-injectors market is set to reach a significant valuation of US$ 30,578.2 million in 2023, marking a strong ...

On the way, it acquired Sanofi India's vaccine portfolio, which has helped it deliver double-digit domestic growth in the ...

The companies did not provide detailed data for Tezspire, however, and William Blair’s Matt Phipps said in a note he does not ...

GAITHERSBURG, Md., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical ...

Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced the appointment of Greg Weaver as Chief Financial Officer ...

The acquisition of global rights to NJO from Sanofi is expected to contribute positively to EBITDA from 2025 onwards. Recordati SpA (RICFY) reported a robust free cash flow of 434.3 million euros, up ...

Corbus Pharmaceuticals still shows promise, with CRB-701 and CRB-601 advancing in clinical trials. Read why CRBP stock is ...

Revenue for Emcure Pharma Q2 rose by over 20%, totaling ₹2,002 Crore, driven by strong performance across segments.

In an exclusive interview with Nigeria Health Watch, Dr Mukhtar outlined the Executive Order's two-year validity, and its transformative provisions. Central to this includes the removal of tariffs, ...